MX378262B - Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienen. - Google Patents

Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienen.

Info

Publication number
MX378262B
MX378262B MX2017012643A MX2017012643A MX378262B MX 378262 B MX378262 B MX 378262B MX 2017012643 A MX2017012643 A MX 2017012643A MX 2017012643 A MX2017012643 A MX 2017012643A MX 378262 B MX378262 B MX 378262B
Authority
MX
Mexico
Prior art keywords
proton pump
pump inhibitor
enteric
pellets containing
stage
Prior art date
Application number
MX2017012643A
Other languages
English (en)
Other versions
MX2017012643A (es
Inventor
Los Mario Atilio
Original Assignee
Laboratorios Bago S A
Eastbrand Holding Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53724266&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX378262(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Laboratorios Bago S A, Eastbrand Holding Gmbh filed Critical Laboratorios Bago S A
Publication of MX2017012643A publication Critical patent/MX2017012643A/es
Publication of MX378262B publication Critical patent/MX378262B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica de estructura benzimidazólica, útiles para preparar composiciones farmacéuticas multiparticuladas de uso oral, que comprende las etapas de: I) recubrir núcleos de celulosa pura con una suspensión hidroalcohólica que contiene el inhibidor de la bomba protónica, un aminoácido dibásico y polivinilpirrolidona; II) aislar los núcleos de celulosa pura recubiertos obtenidos en la Etapa I; III) aplicar un recubrimiento entérico a las partículas obtenidas en la Etapa II anterior; y IV) secar las partículas obtenidas en Etapa III anterior y separar por tamaño. La composición farmacéutica multiparticulada, bajo la forma de comprimidos de desintegración oral, polvo para suspensión de uso oral o cápsulas de uso oral, comprende pellets entéricos, con un diámetro promedio entre 350 y 500 micras y un contenido de un inhibidor de la bomba protónica de estructura benzimidazólica superior al 10.5%, obtenidos con el procedimiento indicado anteriormente.
MX2017012643A 2015-03-31 2015-03-31 Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienen. MX378262B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2015/056982 WO2016155786A1 (en) 2015-03-31 2015-03-31 Enteric-coated pellets containing a proton pump inhibitor

Publications (2)

Publication Number Publication Date
MX2017012643A MX2017012643A (es) 2018-08-01
MX378262B true MX378262B (es) 2025-03-10

Family

ID=53724266

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017012643A MX378262B (es) 2015-03-31 2015-03-31 Procedimiento de elaboración de pellets entéricos que contienen un inhibidor de la bomba protónica y composiciones farmacéuticas multiparticuladas que los contienen.

Country Status (17)

Country Link
US (2) US10786458B2 (es)
EP (1) EP3277267B1 (es)
CN (1) CN107530294B (es)
AR (1) AR103520A1 (es)
AU (1) AU2015389109B2 (es)
BR (1) BR112017020790A2 (es)
CA (1) CA2977168C (es)
CL (1) CL2017002424A1 (es)
CO (1) CO2017010900A2 (es)
HK (1) HK1245087A1 (es)
MX (1) MX378262B (es)
PH (1) PH12017501363A1 (es)
RU (1) RU2679652C1 (es)
SG (1) SG11201706209TA (es)
UA (1) UA120715C2 (es)
UY (1) UY36512A (es)
WO (1) WO2016155786A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10570131B2 (en) 2015-03-31 2020-02-25 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
EP3496714A4 (en) 2016-08-11 2020-04-22 Adamis Pharmaceuticals Corporation DRUG COMPOSITIONS.
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
CN115414471B (zh) * 2022-09-22 2026-01-02 南京正科医药股份有限公司 一种托拉塞米片及其制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8404808L (sv) 1983-10-03 1985-04-04 Avner Rotman Mikrokapslat lekemedel i sot matris
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
DE69331839T2 (de) 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
JP3746167B2 (ja) * 1998-05-18 2006-02-15 武田薬品工業株式会社 医薬製剤
PT1018340E (pt) * 1999-01-06 2003-12-31 Tecnimede Sociedade Tecnico Medicinal Sa Complexos de inclusao de sais de aminoacidos de derivados do benzimidazol com ciclodextrinas, sua preparacao e formulacoes farmaceuticas que os contem
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
WO2004062552A2 (en) 2003-01-09 2004-07-29 Galephar M/F Pharmaceutical composition containing a nsaid and a benzimidazole derivative
DE602004025113D1 (de) * 2003-07-11 2010-03-04 Astrazeneca Ab Feste zusammensetzung mit einem protonenpumpenhemmer
CN1263450C (zh) * 2005-01-20 2006-07-12 北京科信必成医药科技发展有限公司 奥美拉唑及其衍生物的口腔崩解片及其制备工艺
CN100393304C (zh) * 2005-02-28 2008-06-11 上海艾力斯医药科技有限公司 一种包含酸不稳定药物的微细颗粒及其制剂
WO2006134611A1 (en) * 2005-06-16 2006-12-21 Hetero Drugs Limited Compositions of antiulcerative substituted benzimidazoles
US20070141151A1 (en) * 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP1813275A1 (en) 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
CN100490790C (zh) * 2007-04-28 2009-05-27 杭州民生药业集团有限公司 一种奥美拉唑肠溶微丸胶囊及其制备方法
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
DE102008045339A1 (de) * 2008-09-01 2010-03-04 Stada Arzneimittel Ag Pharmazeutisches Pellet
US20120058194A1 (en) * 2010-08-27 2012-03-08 Navin Vaya Pharmaceutical formulations comprising substituted benzimidazole derivatives
CN102526049A (zh) * 2012-02-04 2012-07-04 神威药业有限公司 一种复方双氯芬酸钠缓释制剂及其制备方法
US9668978B2 (en) * 2012-03-20 2017-06-06 Laboratorios Bago S.A. Method for producing enteric alginate microcapsules via ionic gelation containing diclofenac or one of the salts thereof and multiparticled pharmaceutical composition containing them

Also Published As

Publication number Publication date
CL2017002424A1 (es) 2018-04-13
CN107530294B (zh) 2021-11-30
AU2015389109A1 (en) 2017-08-17
MX2017012643A (es) 2018-08-01
PH12017501363B1 (en) 2017-12-18
UA120715C2 (uk) 2020-01-27
CA2977168A1 (en) 2016-10-06
PH12017501363A1 (en) 2017-12-18
EP3277267A1 (en) 2018-02-07
RU2679652C1 (ru) 2019-02-12
HK1245087A1 (zh) 2018-08-24
US20200390709A1 (en) 2020-12-17
BR112017020790A2 (pt) 2018-06-26
CO2017010900A2 (es) 2018-01-16
EP3277267B1 (en) 2021-01-06
WO2016155786A1 (en) 2016-10-06
CN107530294A (zh) 2018-01-02
US10786458B2 (en) 2020-09-29
US20180078505A1 (en) 2018-03-22
UY36512A (es) 2016-08-31
SG11201706209TA (en) 2017-10-30
AR103520A1 (es) 2017-05-17
AU2015389109B2 (en) 2021-04-01
CA2977168C (en) 2020-01-28

Similar Documents

Publication Publication Date Title
PH12017501363A1 (en) Enteric-coated pellets containing a proton pump inhibitor
WO2018132739A3 (en) T cell receptors that bind to ny-eso-1 and methods of use thereof
MX2016014320A (es) Composiciones de suspension de liberacion prolongada.
MX357575B (es) Recubrimientos de pelicula de liberacion retardada que contienen silicato de calcio y sustratos recubiertos con los mismos.
BR112015012547A2 (pt) composições de prostaciclina e métodos de sua utilização
BR112015022770A2 (pt) métodos e materiais para diferenciação hematoendotelial de células-tronco pluripotentes humanas sob condições definidas
WO2011159726A3 (en) Reprogramming of cells to a new fate
JO3306B1 (ar) تراكيب وطرق لطلاء الأظافر قابل للمعالجة بالأشعة فوق البنفسجية
MX2015013039A (es) Encapsulados polimericos con mezcla de ceras.
AR128816A2 (es) Formas de dosificación farmacéutica de perlas de cisteamina
BR112017011773A2 (pt) composto isolado, conjugados isolados, composiçôes farmacêuticas, e métodos de tratamento de um distúrbio em um mamífero
BR112015012808A2 (pt) composição de cuidado oral
MX2018005415A (es) Composicion formadora de pelicula dental duradera y usos de esta.
MX2015011166A (es) Composicion curable fotocromica.
GB2538031A (en) Methods of producing particles having two different properties
HK1257171A1 (zh) 間變性淋巴瘤激酶（alk）和絲氨酸富集蛋白激酶 （sppk）的抑制劑及其使用方法
BR112016014486A2 (pt) Composição de enxágue bucal e uso
NZ627468A (en) Hydrocortisone controlled release formulation
GB2514741A (en) Composition for use as a paint binder
PH12016501525A1 (en) Water-based epoxy formulations for applied fireproofing
NZ607225A (en) Multiple unit tablet composition
PH12016502048A1 (en) Water-based epoxy formulations for applied fireproofing
MX2017003555A (es) Proceso para elaborar un nucleo con un revestimiento activo.
WO2014111956A3 (en) Sustained release formulations of curcuminoids and method of preparation thereof
PH12017501466A1 (en) An oral pharmaceutical formulation comprising sustained-release granules containing tamsulosin hydrochloride